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The study was carried out on type 2 diabetic obese patients who underwent laparoscopic sleeve gastrectomy (LSG). Patients
underwent regular glycemic controls throughout 3 years and all patientswere defined cured fromdiabetes according to conventional
criteria defined as normalization of fasting glucose levels and glycated hemoglobin in absence of antidiabetic therapy. After 3 years
of follow-up, Continuous Glucose Monitoring (CGM) was performed in each patient to better clarify the remission of diabetes. In
this study, we found that the diabetes resolution after LSG occurred in 40% of patients; in the other 60%, even if they showed a
normal fasting glycemia and A1c, patients spent a lot of time in hyperglycemia. During the oral glucose tolerance test (OGTT), we
found that 2 h postload glucose determinations revealed overt diabetes only in a small group of patients and might be insufficient
to exclude the diagnosis of diabetes in the other patients who spent a lot of time in hyperglycemia, even if they showed a normal
glycemia (<140mg/dL) at 120 minutes OGTT.These interesting data could help clinicians to better individualize patients in which
diabetes is not resolved and who could need more attention in order to prevent chronic complications of diabetes.
1. Introduction
The prevalence of type 2 diabetes mellitus (T2DM) is rapidly
increasing worldwide in parallel with the current obesity
epidemic. In 2010 the global prevalence of type 2 diabetes
was estimated at 8.3% of the adult population and 23% of
patients with morbid obesity have type 2 diabetes. These
data are projected to increase and prevalence of diabetes is
expected to reach 9.9% by 2030 [1]. Conventional medical
treatment of type 2 diabetesmay achieve only partial glycemic
control and reduction of cardiovascular risk [2], especially if
associated with obesity. As known, management of diabetes
is particularly challenging in morbidly obese patients.
Although initially developed solely as a weight reduction
therapy, bariatric surgery has been reported to cure and
improve type 2 diabetes and to reduce rates of cardiovascular
disease and death [3–6].
A meta-analysis of studies [7] on various bariatric pro-
cedures involving patients with type 2 diabetes showed an
overall rate of remission of hyperglycemia of 78% among
the various procedures. Remission occurred in approximately
half of patients who underwent Laparoscopic Adjustable
Gastric Banding (LAGB), 80% of those who underwent
Roux-en-Y gastric bypass, and 95% of those who underwent
biliopancreatic diversion (BPD).
Data regarding diabetes remission following Laparo-
scopic Sleeve Gastrectomy (LSG) are extremely variable
amongst authors. In a meta-analysis [8] that analyzed 27
studies and 673 patients, diabetes remission was reported
in 66.2% of cases and improvement was reported in 26.9%
of cases. In our previous studies diabetes remitted in 80%
of patients [9, 10], results that have been predominantly
confirmed by a recently published meta-analysis by Yu et al.
[11].
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Busetto et al. showed a direct correlation between weight
loss and the remission of diabetes following various surgical
procedures [12].
Bariatric literature usually presents results in terms of
rate of diabetes cure or remission, usually defined as the
normalization of glucose levels and glycated hemoglobin
(A1c) in the absence of active antidiabetic therapy [13]. In
analogy to the oncologic literature, where cure is defined as
complete remission of cancer of sufficient duration that the
future risk of recurrence is felt to be very low, experts agreed
that itmaymake sense, on a practical ground, to consider pro-
longed (arbitrarily 5 years) remission of diabetes essentially
equivalent to cure. Experts agreed that it may make sense, on
a practical ground, to consider prolonged (arbitrarily 5-year)
remission of diabetes essentially equivalent to cure.
In this context, authors have defined the following condi-
tions. “Partial remission” is A1c < 6.5% and fasting glucose
between 100 and 125mg/dL for a period of at least 1 year’s
duration in the absence of active pharmacologic therapy.
“Complete remission” is a return to “normal” values of
glucose metabolism (A1c < 6%, fasting glucose < 100mg/dL)
for at least 1 year’s duration. “Prolonged remission” is com-
plete remission that lasts for more than 5 years [13].
However, the remission or reoccurrence of diabetes after
surgery is difficult to establish. Oral glucose tolerance tests
(OGTT) are difficult to interpret both because of themodified
glucose kinetics after surgery and because of the lack of
reference data which define a “normal” OGTT after bariatric
surgery.
Another question that arises from bariatric literature
is the correct diagnosis of diabetes, both before and after
surgery. Diagnosis of diabetes should be always performed
according to ADA (American Diabetes Association) guide-
lines [14] which, besides other criteria, take into account a
detection of random glycemia over 200mg/dL during the
day. Bariatric surgeons usually assess the presence of type 2
diabetes mellitus before surgery on the basis of the existing
oral treatment regimen of patients (e.g., metformin treat-
ment); following surgery they often define diabetes remission
on the basis of fasting glycemia values, without a specific
consideration to postprandial glycemic peaks.
It is now widely known that acute fluctuations of glucose
around a mean value over a daily period of intermittent
hyperglycemia may play an important role in the develop-
ment of cardiovascular disease in type 2 diabetic patients
[15, 16].
Fasting plasma glucose is usually normalized in post-
bariatric patients, while little is known about their glucose
profiles throughout the day, especially immediately after
meals, and about how this variability can affect the develop-
ment of future micro- and macrovascular complications.
In literature, only few cases undergoing gastric bypass
have been assessed through Continuous Glucose Monitoring
(CGM). These cases show early hyperglycemic peaks after
either a meal test or a glucose load, followed by a rapid
fall to very low glycemic levels, with postprandial symptoms
as seen in dumping syndrome. However, these authors
have focused their attention only on the use of CGM in
relation to hypoglycemia resulting from the operation [17, 18].
Regarding LSG, there are few recent data about diabetes
remission investigated by CGM [19].
The aim of this study was to evaluate glucose variability
assessed by CGM in obese type 2 diabetic patients that
underwent LSG, who were defined as cured of diabetic
disease according to international criteria, which consist in
fasting glycemia < 100mg/dL and A1c < 6% in absence of
hypoglycemic therapy.
2. Subjects and Methods
2.1. Study Design
2.1.1. Recruitment. A total of 20morbidly obese patients were
enrolled 3 years following LSG to perform CGM to evaluate
glucose plasma variability and OGTT for glucose tolerance
evaluation.
Patients were recruited at the Centre of Diabetes and
Metabolic Diseases of Sapienza University in Rome. Exclu-
sion criteria were overt diabetes or use of plasma glucose-
lowering drugs.
All the patients were diabetics before surgery with T2DM
diagnosed according to American Diabetes Association
guidelines [14].
2.1.2. Clinical Outcomes. The primary clinical outcome was
evaluation of real diabetes remission after LSG by assessing
glucose variability by CGM and glucose tolerance by OGTT.
The follow-up lasted at least 42months consisting in clin-
ical examinations with anthropometric measurements and
routine laboratory tests with glucose metabolism assessment
every 3 months. Diabetes remission after LSG was then
defined as a fasting glucose level of less than 100mg/dL and
an A1c level of less than 6% in absence of treatment.
The results were then related with retrospectively col-
lected data, referred to each patient before surgery in order to
look for prognostic factors of the diabetes resolution obtained
by LSG, including anthropometric parameters, duration of
diabetes, age, BMI, insulin use, and fasting C-peptide as
marker of insulin secreting ability.
2.1.3. Variables. The following parameters were recorded at
baseline and three years after surgery:
(i) Age, gender, bodymass index (BMI), and systolic and
diastolic pressure.
(ii) Ongoing drug treatments.
(iii) Fasting blood levels of glucose, A1c, total and HDL
cholesterol, and triglycerides.
2.1.4. Measurements. Standing height, weight, and waist
circumference were measured with subjects wearing light
clothing. Obesity was estimated by means of BMI [weight
(kg) divided by height × height (m2)].
Blood pressure (mmHg) was measured after five minutes
of rest with the patient sitting in the upright position. Three
measurements were obtained, and the average of the second
and third ones was recorded and used in the analysis. Patients
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Table 1: Characteristics of morbidly obese patients with T2DM before and after LSG at time of CGM.
Before LSG After LSG 𝑃
Gender (F/M) 15/5 15/5 —
Age (years) 50.9 ± 8.2 53.1 ± 9.2 —
Weight (kg) 122.7 ± 32.1 78.8 ± 18.6 0.005
BMI (kg/m2) 44.3 ± 8.2 29.7 ± 6.1 0.003
Fasting glucose (mg/dL) 151.8 ± 37.4 83.5 ± 10.7 0.001
A1c (%) 7.4 ± 1.3 5.7 ± 0.6 0.035
Oral hypoglycemic agents/insulin 17/3 0/0 0.015
Diabetes duration (years) 5.3 ± 4.9 — —
underwent fasting blood sampling to assess blood glucose,
A1c, total cholesterol, high-density lipoprotein cholesterol
(HDL), and triglycerides, by standard laboratory methods
carried out by our center.
2.1.5. Surgical Procedure. LSG was performed according to
National Institutes of Health criteria for bariatric surgery
indications [20]. The surgical operation was applied as the
previously described technique [21] in which five trocars are
needed.The division of the gastric greater curvature vascular
supply, starting at 6 cm from the pylorus and proceeding
upwards until the angle of His, is carried out with radiofre-
quency (Harmonic Scalpel, Ethicon EndoSurgery) or with
Caiman 5mm vessel sealing device (Aesculap). The gastric
resection was performed using a linear stapler (ECHELON
FLEX ENDOPATH STAPLER, Ethicon EndoSurgery), with
two sequential green load firings for the antrum, followed
by three or four sequential gold loads for the remaining
gastric corpus and fundus. The stapler is applied alongside
a 42 Fr calibrating bougie strictly positioned against the
lesser curve, to obtain an 80–100mL gastric volume. The last
shot of stapling was fired at least 1 cm distal to the esoph-
agogastric junction. Reinforcement of the staple lines was
performed with bioabsorbable strips (GORE SEAMGUARD
Bioabsorbable Staple Line Reinforcement). Intraoperative
methylene blue test was routinely performed at the end of the
procedure to check for gastric leak and to evaluate the volume
and the shape of the sleeve and a drain was routinely placed.
The resected stomach was extracted in a retrieval bag.
2.1.6. CGM. The CGM sensor (Medtronic iPro 2 digital
recorder, MMT-7741) was attached to the abdomen of the
patients by a serter and was held in place for 6 days. The first
CGMS calibrationwas performed 1 h after initialization using
blood from a finger prick. By using a glucometer, patients
were asked to record three daily glycemic measurements in
a diary that were necessary to obtain correct calibration of
the recorder. The CGM profiles of the patients were then
analyzed with software that enables automatic extraction
of the necessary data and subsequent generation of graphs
and the area under the curves. On day 6, the subjects
returned to the hospital in the morning in fasting state
for an oral glucose tolerance test (OGTT); measurement of
plasma glucose at 0󸀠-30󸀠-60󸀠-90󸀠-120󸀠 was performed during
the CGM; and the CGM was stopped 2 hours after glucose
load. In each patient the total AUC for glycemia during
OGTT was calculated. During the CGM, the percentage
of time conventionally spent in physiological range (70–
140mg/dL), under the physiological range (<70mg/dL), and
in the hyperglycemic range (>140mg/dL) was assessed. AUC
(area under the curve) above the limit of 140mg/dL and
AUC below the limit of 70mg/dL were calculated during the
CGM. In addition, standard deviation, as index for glycemic
variability, glycemic peaks, and nadir during daily life, was
evaluated.
2.1.7. Ethics. The study was reviewed and approved by the
institutional human ethics committee in accordance with
national guidelines and the provisions of the Helsinki Dec-
laration, as revised in 2000. All patients provided written
informed consent to participate in the study, and additional
written informed consent was obtained before any surgical
procedure.
2.1.8. Statistics. Clinical characteristics of the study partici-
pants were reported as mean and SD for continuous variables
and frequencies andpercentages for categorical variables. Sta-
tistical analyses were performed using SPSS software version
15.0 (SPSS, Inc., Chicago, IL, USA). Statistical significance
was set at 𝑃 < 0.05.
3. Results
All patients included in the study had been defined as
cured according to the international criteria for diabetes
remission [13]. Anthropometric and biochemical parameters
and diabetes duration and treatment, before and after LSG,
are reported in Table 1.
The data obtained by CGM were analyzed and showed a
very different pattern of glycemic curves, suggesting that we
differentiate patients with hyperglycemic values (convention-
ally defined >140mg/dL) from the others who did not spend
time in hyperglycemia. Therefore, we divided subjects into
two groups.
(i) Group A: patients who spent no time with glycemia
over 140mg/dL (example of CGM of one patient of
this group is reported in Figure 1(a)).
(ii) Group B: patients who spent part of their time in
hyperglycemia, defined over 140mg/dL (example of
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Table 2: Criteria for diabetes remission (fasting glycemia and A1c) and CGM and OGTT data in groups A and B.
Group A Group B 𝑃
BG fasting (mg/dL) 79.7 ± 11.8 87.1 ± 8.5 n.s.
A1c (%) 5.5 ± 0.4 5.6 ± 0.5 n.s.
BG at 120󸀠 OGTT (mg/dL) 87.3 ± 4.2 147.1 ± 59.4 0.04
0󸀠–120󸀠 glycemia AUC during OGTT (mg dL−1min) 17902.5 ± 5552.1 19940.4 ± 5149.1 n.s.
0󸀠–90󸀠 glycemia AUC during OGTT (mg dL−1min) 12345.6 ± 20008.3 16587.0 ± 3502.8 0.02
CGM time with glycemia >140mg/dL (%) 0 21.4 ± 8.06 0.002
CGM AUC plasma glucose >140mg/dL (mg dL−1min) 0 8.0 ± 6.2 0.06
CGM time with glycemia <70mg/dL (%) 5 ± 1 2.6 ± 0.8 n.s.
CGM AUC plasma glucose <70mg/dL (mg dL−1min) 0.7 ± 0.1 0.14 ± 0.05 n.s.
CGM glycemic peak (mg/dL) 156.2 ± 12.6 241.2 ± 70.5 0.03
CGM glycemic nadir (mg/dL) 52.2 ± 12.2 63.1 ± 11.1 n.s.
CGM variability (SD) 16.8 ± 5.24 30.0 ± 9.9 0.02
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Figure 1: CGM profile in one patient of group A and in one patient of group B.
CGM of one patient of this group is reported in
Figure 1(b)).
Patients of group A were defined as “cured” of diabetes and
patients of group B were defined as “not cured.”
Glycemic peak and nadir during CGM are reported for
both groups of patients in Table 2.
In patients of group A (8/20), 2 h OGTT showed physi-
ologic glycemic peak at 30 minutes and at 120󸀠 glycemia was
<140mg/dL. These patients were then considered “cured” of
diabetes either by international criteria for diabetes remission
for bariatric patients or by OGTT criteria, showing a normal
glucose tolerance. In these subjects, during everyday life
conditions, glycemia assessed by CGM never exceeded the
140mg/dL levels.
In patients of group B (12/20), 2 h OGTT showed a
delayed glycemic peak not earlier than 60 minutes and
sometimes delayed at 90 minutes; 8 out of 12 patients of this
group achieved normal levels at 120󸀠 OGTT (<140mg/dL),
whilst the other patients remained higher than 200mg/dL
as usually occurs in diabetic patients. These patients spent
from 13% to 45%of timewith glycemia higher than 140mg/dL
during the CGM. Therefore, even if these patients showed a
normal fasting glucose and normal A1c values, we decided to
define them as “not cured” from diabetes.
2 h OGTT glycemic levels in each single patient of both
groups are reported in Figure 2.
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Table 3: Differences between group A and group B regarding age, BMI, insulin therapy, A1c, C-peptide, diabetes duration, and weight loss.
Group A Group B 𝑃
Age (years) 48.4 ± 8.2 52.0 ± 8.5 0.02
Preoperative BMI (kg/m2) 45.1 ± 7.2 42.8 ± 7.4 0.04
Insulin use (number of patients) 0/8 3/12 —
A1c before surgery (%) 7.5 ± 1.0 7.4 ± 1.0 —
C-peptide before surgery (ng/mL) 5.2 ± 1.5 3 ± 0.5 0.02
Diabetes duration before surgery (years) 2.5 ± 2.3 6.5 ± 4.5 0.04
Total weight loss after surgery (%) 33.7 ± 13.9 31.6 ± 11.8 —
EWL after surgery (%) 63.8 ± 26.3 69.1 ± 16.8 —
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Figure 2: Glycemia during 2 h OGTT in each patient of group A (a) and group B (b).
International criteria to exclude diabetes (fasting glyce-
mia, A1c) and data obtained fromOGTT andCGM in groups
A and B are reported in Table 2.
The 2 h OGTT glycemia AUC in the two intervals of 0–
120minutes and 0–90minutes has been calculated and added
in Table 2 in groups A and B. The interval of 0–90 minutes
has been investigated in consideration of the rapid gastric
emptying due to LSG.
Retrospective assessment of anthropometric parameters,
insulin use, A1c, fasting plasma C-peptide as marker of
insulin secreting ability before surgery, and duration of diabe-
tes was then compared in groups A and B as reported in
Table 3.
4. Discussion
Since the pioneering reports of the last decade of the twen-
tieth century [22, 23], the efficacy of bariatric procedures
in improving and even normalizing glucose levels in obese
patients with type 2 diabetes has been confirmed by a large
number of observational studies [7].
However, while fasting plasma glucose concentrations are
usually normalized in these patients, little is known about
their glucose profiles throughout the day and particularly
after meals.
In literature, there are only a few reports that adopt
CGM following bariatric surgery, mainly aiming to assess
hypoglycemia due to dumping syndrome after gastric bypass
[17, 18].
This study adds something new to the knowledge of
glucose variability and tolerance using the CGM and OGTT
in patients that underwent LSG. It aims to assess glycemia
throughout the day, as a means of investigating the real
remission of diabetes, considering that fasting glucose and
A1cmight be insufficient to exclude the persistence or relapse
of diabetes after surgery.
According to international guidelines on the definition of
glycemic outcomes after bariatric surgery, all patients of this
study had been defined as “cured” from diabetes 3 years after
LSG.
However, we found that an unexpected 60% of these
patients experienced significant hyperglycemia revealed by
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CGM during their everyday life, and in some cases overt
diabetes was seen with glycemia > 200mg/dL at 120 minutes
of OGTT.
The results obtained by OGTT and CGM allowed con-
firming that patients appear really cured of diabetes only in
group A (40%). In fact according to CGM these patients
spent no time with glycemia over 140mg/dL, even after
meals. Surprisingly, a number of patients (group B) showed
variable time with glycemia over 140 during CGM, often
associatedwith very high glycemic postprandial levels, lasting
approximately 40% of daily time. They also had a delayed
glycemic peak at 60 minutes after oral glucose load which
remained high until 90 minutes.
In literature, data are not available to clarify the correct
interpretation of OGTT after bariatric surgery; the lack of
this information might be one of the reasons the test is not
included in the criteria of diabetes remission in bariatric
operated patients. In our opinion, it is not reasonable to apply
the standard OGTT criteria in operated subjects because the
surgical procedure causesmodified glucose kinetics due to an
accelerated transit of food in the stomach [24].
In “cured” patients, who did not spend any time in
hyperglycemia during CGM, glycemic OGTT peak occurred
at the first measurement at 30 minutes, while at 90 minutes
these patients showed glycemic values similar to basal values.
On the contrary, in “not cured” patients, who spent a long
time in hyperglycemia during CGM, the glycemic peak
during OGTT occurred at 60–90 minutes with very high
values.This effect demonstrates impaired insulin secretion in
these patients as suggested by preoperative C-peptide levels.
The massive secretory response of beta-cells to these very
high and durable glycemic levels is able to rapidly reduce the
glycemic levels to values of less than 140mg/dL, suggesting
normal glucose tolerance. In fact, these patients might be
considered at high risk of diabetes recurrence. Therefore, at
2 h after glucose load, plasma glucose determinations may
be misleading, and assessment of glycemia at thirty-minute
intervals throughout the test is important.
Four diabetic patients of group B were defined as “cured”
according to fasting glycemia and A1c before performing
OGTT and CGM, but, in fact, elevated OGTT glycemic
values diagnostic for overt diabetes (glycemia > 200mg/dL at
120 minutes) were found. Furthermore, these patients spent
about 40% of time during CGM with glycemia higher than
140mg/dL and occasionally even higher than 200mg/dL.
Recent studies using CGM showed significant fluctua-
tions in blood glucose values even in patients with excellent
A1c plasma levels. These data suggest that glucose variability
may have a predictive role for the development of the
complications of diabetes [25, 26]. Moreover Kilpatrick et
al. [27] analyzed the Diabetes Control and Complications
Trial (DCCT) patient cohort and observed that blood glucose
instability is not a predictor of microvascular complications
(mainly retinopathy) [28], but, on the other hand, mean daily
glucose values, as well as the pre- and postprandial glucose
ones, are predictors of cardiovascular disease [29].
Data are less consistent in T2DM. Several years ago,
Muggeo et al. found that all-cause and cardiovascular mor-
tality in elderly people with diabetes [30] were primarily
associated with the variability/instability of glucose levels,
rather than its absolute values.
The clinical use of CGM in this study allowed us to
monitor the daily glycemic profile after LSG, which revealed
unexpected hyperglycemia. By using CGM we found that
only 40% of patients had complete hyperglycemia remission
after LSG, although all patients had been considered “cured”
according to existing standard definitions of glycemic out-
comes after bariatric surgery. Our hypothesis is that A1c was
not reliable in these cases, probably because of the short
duration of hyperglycemic peaks that may have been too
rapid for glycation of hemoglobin, even when glycemic peaks
were very high.
Furthermore, we did not observe a balance between
hyper- and hypoglycemia, as reported in gastric bypass
surgery [17, 18] that could explain normal A1c values. In
fact, in patients that underwent LSG, the percentage of time
spent with glycemia less than 70mg/dL was only 3.9% in all
patients, exactly 5% in group A and 2.6% in group B.
In order to identify prognostic factors for complete dia-
betes remission, we compared the two groups prior to surgery
by considering age, diabetes duration, beta-cell function, and
insulin use.
There is generally agreement among the published studies
that patients who have long-standing T2DM have a lower
remission rate after bariatric surgery, probably due to their
poor residual beta-cell function [31]. Other preoperative
patient factors have been associated with the outcomes of
diabetes remission, including age, fasting C-peptide concen-
tration, BMI, glycemic control (A1c), and medications used
tomanage blood glucose, including oral hypoglycemic agents
and insulin [32].
As described in a previous study [33], diabetes duration
is the main prognostic factor for diabetes remission after
LSG. In fact, we published the fact that patients with history
of less than 10 years of diabetes were cured from diabetes,
according to standard criteria for diabetes remission (e.g.,
fasting glucose (<100mg/dL) and A1c (<6%)).
We observed that although all patients had a duration of
diabetes of less than 10 years, patients of groupAhad a shorter
diabetes duration (maximum 2 years) than patients of group
B. Furthermore, patients with diabetes remission after LSG
were younger, with higher fasting plasma levels of C-peptide,
with higher BMI, and without insulin therapy before surgery.
The limits of this study were small sample size and small
subgroups according to CGM results, and data was collected
only after surgery. Further evaluations in a larger number of
diabetics with morbid obesity, studied before and after the
bariatric surgical operations, will be performed in order to
give us more details on this topic.
5. Conclusions
Bariatric surgery significantly improves the prognosis of
obese patients and improves the overall glycemic control
in obese diabetics. We reported glucose variability in a
real-life setting for the first time, assessed by CGM after
LSG in patients defined as “cured” of diabetes according
to international guidelines on remission of diabetes after
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bariatric procedures.The clinical relevance of this study con-
sists in an insight into glycemia levels in carefully monitored
diabetic patients that underwent LSG. We recommend 2 h
OGTT, checking glycemia not only at 120 minutes, but also
at every 30 minutes, in patients that are apparently cured
of diabetes by standard criteria but that are still exposed
to significant glucose variability which could cause future
chronic complications of diabetic disease.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
Acknowledgment
The authors thank Medtronic Italia S.p.A. for the precious
technical assistance.
References
[1] International Diabetes Federation, IDF Diabetes Atlas, Interna-
tional Diabetes Federation, Brussels, Belgium, 5th edition, 2011,
http://www.idf.org/diabetesatlas.
[2] A. Liebl, M. Mata, and E. Eschwe`ge, “Evaluation of risk factors
for development of complications inType II diabetes in Europe,”
Diabetologia, vol. 45, no. 6, pp. S23–S28, 2002.
[3] L. Sjo¨stro¨m, A.-K. Lindroos, M. Peltonen et al., “Lifestyle,
diabetes, and cardiovascular risk factors 10 years after bariatric
surgery,”The New England Journal of Medicine, vol. 351, no. 26,
pp. 2683–2693, 2004.
[4] L. Sjo¨stro¨m, K. Narbro, C. D. Sjo¨stro¨m et al., “Effects of bariatric
surgery on mortality in Swedish obese subjects,” The New
England Journal of Medicine, vol. 357, no. 8, pp. 741–752, 2007.
[5] L. Sjo¨stro¨m, M. Peltonen, P. Jacobson et al., “Bariatric surgery
and long-term cardiovascular events,”The Journal of the Amer-
ican Medical Association, vol. 307, no. 1, pp. 56–65, 2012.
[6] G. Mingrone, S. Panunzi, A. De Gaetano et al., “Bariatric
surgery versus conventional medical therapy for type 2 dia-
betes,” The New England Journal of Medicine, vol. 366, no. 17,
pp. 1577–1585, 2012.
[7] H. Buchwald, R. Estok, K. Fahrbach et al., “Weight and type
2 diabetes after bariatric surgery: systematic review and meta-
analysis,” The American Journal of Medicine, vol. 122, no. 3, pp.
248.e5–256.e5, 2009.
[8] R. S. Gill, D. W. Birch, X. Shi, A. M. Sharma, and S. Karmali,
“Sleeve gastrectomy and type 2 diabetes mellitus: a systematic
review,” Surgery for Obesity and Related Diseases, vol. 6, no. 6,
pp. 707–713, 2010.
[9] F. Leonetti, D. Capoccia, F. Coccia et al., “Obesity, type 2
diabetes mellitus, and other comorbidities: a prospective cohort
study of laparoscopic sleeve gastrectomy vs medical treatment,”
Archives of Surgery, vol. 147, no. 8, pp. 694–700, 2012.
[10] F. Abbatini, D. Capoccia, G. Casella, F. Coccia, F. Leonetti,
and N. Basso, “Type 2 diabetes in obese patients with body
mass index of 30–35 kg/m2: sleeve gastrectomy versus medical
treatment,” Surgery for Obesity and Related Diseases, vol. 8, no.
1, pp. 20–24, 2012.
[11] J. Yu, X. Zhou, L. Li et al., “The long-term effects of bariatric
surgery for type 2 diabetes: systematic review andmeta-analysis
of randomized and non-randomized evidence,”Obesity Surgery,
vol. 25, no. 1, pp. 143–158, 2015.
[12] L. Busetto, P. Sbraccia, L. Frittitta, and A. E. Pontiroli, “The
growing role of bariatric surgery in the management of type 2
diabetes: evidences and open questions,” Obesity Surgery, vol.
21, no. 9, pp. 1451–1457, 2011.
[13] S. A. Brethauer, A. Aminian, H. Romero-Talama´s et al., “Can
diabetes be surgically cured? Long-term metabolic effects of
bariatric surgery in obese patients with T2DM,” Annals of
Surgery, vol. 258, no. 4, pp. 628–637, 2013.
[14] American Diabetes Association, “Standards of Medical Care in
Diabetes-2013,” Diabetes Care, vol. 36, supplement 1, pp. S11–
S66, 2013.
[15] C.-M. Ma, F.-Z. Yin, R. Wang et al., “Glycemic variability
in abdominally obese men with normal glucose tolerance as
assessed by continuous glucose monitoring system,” Obesity,
vol. 19, no. 8, pp. 1616–1622, 2011.
[16] C. Wang, L. Lv, Y. Yang et al., “Glucose fluctuations in subjects
with normal glucose tolerance, impaired glucose regulation and
newly diagnosed type 2 diabetes mellitus,” Clinical Endocrinol-
ogy, vol. 76, no. 6, pp. 810–815, 2012.
[17] P. Ritz, C. Vaurs, M. Bertrand, Y. Anduze, E. Guillaume, and
H. Hanaire, “Usefulness of acarbose and dietary modifications
to limit glycemic variability following Roux-en-Y gastric bypass
as assessed by continuous glucose monitoring,” Diabetes Tech-
nology andTherapeutics, vol. 14, no. 8, pp. 736–740, 2012.
[18] H. Hanaire, M. Bertrand, B. Guerci, Y. Anduze, E. Guillaume,
and P. Ritz, “High glycemic variability assessed by continuous
glucosemonitoring after surgical treatment of obesity by gastric
bypass,”Diabetes Technology andTherapeutics, vol. 13, no. 6, pp.
625–630, 2011.
[19] A. Jime´nez, A. Ceriello, R. Casamitjana, L. Flores, J. Viaplana-
Masclans, and J. Vidal, “Remission of type 2 diabetes after Roux-
en-Y gastric bypass or sleeve gastrectomy is associated with a
distinct glycemic profile,” Annals of Surgery, vol. 261, no. 2, pp.
316–322, 2015.
[20] “NIH consensus statement covers treatment of obesity,” The
American Family Physician, vol. 44, no. 1, pp. 305–306, 1991.
[21] N. Basso, D. Capoccia, M. Rizzello et al., “First-phase insulin
secretion, insulin sensitivity, ghrelin, GLP-1, and PYY changes
72 h after sleeve gastrectomy in obese diabetic patients: the
gastric hypothesis,” Surgical Endoscopy, vol. 25, no. 11, pp. 3540–
3550, 2011.
[22] W. J. Pories, M. S. Swanson, K. G. MacDonald et al., “Who
would have thought it? An operation proves to be the most
effective therapy for adult-onset diabetes mellitus,” Annals of
Surgery, vol. 222, no. 3, pp. 339–352, 1995.
[23] K. G. MacDonald Jr., S. D. Long, M. S. Swanson et al.,
“The gastric bypass operation reduces the progression and
mortality of non-insulindependent diabetes mellitus,” Journal
of Gastrointestinal Surgery, vol. 1, no. 3, pp. 213–220, 1997.
[24] F. Rodieux, V. Giusti, D. A. D’Alessio, M. Suter, and L. Tappy,
“Effects of gastric bypass and gastric banding on glucose
kinetics and gut hormone release,” Obesity, vol. 16, no. 2, pp.
298–305, 2008.
[25] S. Frontoni, P. di Bartolo, A. Avogaro, E. Bosi, G. Paolisso, and
A. Ceriello, “Glucose variability: an emerging target for the
treatment of diabetes mellitus,” Diabetes Research and Clinical
Practice, vol. 102, no. 2, pp. 86–95, 2013.
[26] S. Salardi, S. Zucchini, R. Santoni et al., “The glucose area under
the profiles obtained with continuous glucose monitoring
8 Journal of Diabetes Research
system relationships with HbA1c in pediatric type 1 diabetic
patients,” Diabetes Care, vol. 25, no. 10, pp. 1840–1844, 2002.
[27] E. S. Kilpatrick, A. S. Rigby, and S. L. Atkin, “The effect of
glucose variability on the risk of microvascular complications
in type 1 diabetes,” Diabetes Care, vol. 29, no. 7, pp. 1486–1490,
2006.
[28] E. S. Kilpatrick, A. S. Rigby, and S. L. Atkin, “Effect of glucose
variability on the long-term risk ofmicrovascular complications
in type 1 diabetes,” Diabetes Care, vol. 32, no. 10, pp. 1901–1903,
2009.
[29] E. S. Kilpatrick, A. S. Rigby, and S. L. Atkin, “Mean blood glu-
cose compared with HbA
1𝑐
in the prediction of cardiovascular
disease in patients with type 1 diabetes,”Diabetologia, vol. 51, no.
2, pp. 365–371, 2008.
[30] M. Muggeo, G. Verlato, E. Bonora, G. Zoppini, M. Corbellini,
and R. de Marco, “Long-term instability of fasting plasma
glucose, a novel predictor of cardiovascular mortality in elderly
patients with non-insulin-dependent diabetes mellitus: the
verona diabetes study,” Circulation, vol. 96, no. 6, pp. 1750–1754,
1997.
[31] W. J. Lee, K. Y. Hur, M. Lakadawala et al., “Predicting success
of metabolic surgery: age, body mass index, C-peptide, and
duration score,” Surgery for Obesity and Related Diseases, vol.
9, no. 3, pp. 379–384, 2013.
[32] J. B. Dixon, L.-M. Chuang, K. Chong et al., “Predicting the
glycemic response to gastric bypass surgery in patientswith type
2 diabetes,” Diabetes Care, vol. 36, no. 1, pp. 20–26, 2013.
[33] G. Casella, F. Abbatini, B. Cal`ı, D. Capoccia, F. Leonetti, and N.
Basso, “Ten-year duration of type 2 diabetes as prognostic factor
for remission after sleeve gastrectomy,” Surgery for Obesity and
Related Diseases, vol. 7, no. 6, pp. 697–702, 2011.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
